Summary of Purpose
To determine the safety and efficacy of an oral direct thrombin inhibitor Exanta (ximelagatran) with those of dose adjusted warfarin (coumadin) in preventing stroke and systemic embolic events in patients with atrial fibrillation.Read More →
The following dates are available for this trial. Trial information last updated on 4 September 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Randomized, open-label, parallel-group study with blinded event assessment.